| Autor: |
Partanen, Anu, Turunen, Antti, Silvennoinen, Raija, Valtola, Jaakko, Pyörälä, Marja, Siitonen, Timo, Sikiö, Anu, Putkonen, Mervi, Sankelo, Marja, Penttilä, Karri, Kuittinen, Taru, Mäntymaa, Pentti, Pelkonen, Jukka, Jantunen, Esa, Varmavuo, Ville |
| Předmět: |
|
| Zdroj: |
Journal of Clinical Apheresis; Feb2023, Vol. 38 Issue 1, p33-44, 12p |
| Abstrakt: |
Background: Prospective data on the impact of CD34+ cell loss during cryopreservation and the amount of cryopreserved CD34+ cells infused after high‐dose therapy on hematologic recovery and post‐transplant outcome in multiple myeloma (MM) are scarce. Patients and methods: This post‐hoc study aimed to investigate factors associating with CD34+ cell loss during cryopreservation and the effects of the infusion of a very low number (<1.0 × 106/kg, group A), low number (1–1.9 × 106/kg, group B), and optimal number (≥2 × 106/kg, group C) of thawed viable CD34+ cells on hematologic recovery, progression free survival, and overall survival after autologous stem cell transplantation among 127 patients with MM. Results: In group C, pegfilgrastim use (P = 0.001), plerixafor use (P = 0.039), and older age ≥ 60 years (P = 0.026) were associated with less loss of CD34+ cells during cryopreservation. Better mobilization efficacy correlated with greater CD34+ cell loss in group B (P = 0.013 and P = 0.001) and in group C (P < 0.001 and P < 0.001). Early platelet engraftment was slowest in group A (20 d vs 12 d in group B vs 11 d in group C, P = 0.003). The infused viable CD34+ cell count <1.0 × 106/kg seemed not to have influence on PFS (P = 0.322) or OS (P = 0.378) in MM patients. Conclusions: Cryopreservation impacts significantly on the CD34+ cell loss. A very low number of graft viable CD34+ cells did not affect PFS or OS. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text